Arcutis Biotherapeutics, Inc. Operating Income

Quick Answer

Arcutis Biotherapeutics, Inc. reported Operating Income of -$12.23 million for fiscal year 2025.

Arcutis Biotherapeutics, Inc. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$12.23M +90.5%
2024 -$128.40M +46.7%
2023 -$241.10M +20.1%
2022 -$301.63M -46.0%
2021 -$206.53M -51.1%
2020 -$136.65M -216.8%
2019 -$43.13M -118.6%
2018 -$19.73M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 $8.53M +121.8% +158.4%
June 30, 2025 -$14.61M +70.8% +40.4%
March 31, 2025 -$24.53M +22.4% +37.2%
September 30, 2024 -$39.07M -5.9% +22.0%
June 30, 2024 -$50.08M +25.0% -58.4%
March 31, 2024 -$31.62M +58.5% +14.3%
September 30, 2023 -$36.90M +64.8% +44.7%
June 30, 2023 -$66.76M -1.4% +12.5%
  • Arcutis Biotherapeutics, Inc. showed an increase of +90.5% in Operating Income compared to the prior fiscal year.
  • Over the 2018–2025 period, Arcutis Biotherapeutics, Inc.’s operating income has grown by 38.0% (from -$19.73 million to -$12.23 million).
  • The most recent figure is from Arcutis Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment